Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal

June 3, 2026 04:45 PM EDT DealsR&DAI Al­ny­lam signs its first AI dis­cov­ery deal with RNA spe­cial­ist In­cep­tive Andrew Dunn Senior Biopharma Correspondent Al­ny­lam Phar­ma­ceu­ti­cals an­nounced its first dis­cov­ery-fo­cused AI deal Wednes­day, tap­ping a Sil­i­con Val­ley biotech start­up to see if AI can boost its R&D ef­forts. Al­ny­lam … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER